Seattle Genetics down on ASH presentations

Discussion in 'Seattle Genetics' started by Anonymous, Dec 8, 2014 at 10:44 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    When your life revolves around 1 major conference (ASH) a year, shouldn't your stock go up, not down? Looks like investors are finally getting wise to Seagen - 1 product that has not generated any more use since launch. Average # of cycles continues to decline as docs have figured out that anything more than 4 cycles is a waste of $$. Any increase in sales has come from numerous price increases. Oh that's right, we're not supposed to mention that. Maybe investors are also catching on to our arrogant coke-head CEO. it's about time.
    http://seekingalpha.com/news/2165525-seattle-genetics-down-on-ash-presentations
     

  2. Anonymous

    Anonymous Guest

    One small drug approved and a huge competitor on the horizon....there is your reason for
    bailing on SeaGen....

    Immunotherapy with Bristol-Myers Squibb's nivolumab yielded an 87% response rate in patients with Hodgkin lymphoma whose conditions progressed after chemotherapy, stem cell transplant or therapy with Adcetris, according to a study. Of the 23 patients, 16 experienced tumor shrinkage by at least half, and a complete response was seen in four. Nivolumab works by preventing cancer cells' ability to evade an immune system attack.
     
  3. Anonymous

    Anonymous Guest

    This pretty much sums it up...
    Seattle Genetics: Good Tech, But On The Wrong Path - Seattle Genetics, Inc. (NASDAQ:SGEN) | Seeking Alpha

    http://seekingalpha.com/article/2767275-seattle-genetics-good-tech-but-on-the-wrong-path?uide=22834081&uprof=45&dr=1

    The article underscores how weak the current commercial leadership really is - it fails to state that the only increase in sales has come from numerous price increases the company has taken from an already over-priced therapy that has shown no additional survival benefit. It also fails to mention that this is what happens when your senior commercial leadership has a lot of inbreeding going on - commercial VP's that sleep around with managers and reps. When your upper management is more focused on sex than doing their job, you've got a huge problem. It's only a matter of time until their stock starts to look like their commercial VP's old team - Dendreon.
     
  4. Anonymous

    Anonymous Guest

    Clearly a posting from one of the loser who were fired or jumped ship. Frank, you guys would do much better finding a job versus posting on this website. Clearly you are not an insider since you would know that sales increases have been greater than any price increase. Find another board. Better yet, find a job..
     
  5. Anonymous

    Anonymous Guest

    Thank you for stating the obvious so astutely. I peruse this board about once a month and get irritated whenever I see this rumor mongering crap which barely disguises a disgruntled agenda. Wouldn't it be nice if they channeled their misplaced anger in a different direction, perhaps into something positive to help others?
     
  6. Anonymous

    Anonymous Guest

    ;

    All rumors - you wish! Just like your CEO's white powdery nose problem....

    And when are you going to get a new drug approved...2025?
     
  7. Anonymous

    Anonymous Guest

    So much for being positive. Go slander elsewhere. Your boring. As far as approvals go, anyone who has a brain and pays attention in this industry knows that no-one has a crystal ball regarding the end result of clinical trials and the fda's ultimate decision. So those of us who appreciate a passion for developing therapies to address unmet needs in order to help patients (like yourself or your family, god forbid) appreciate this organization's pipeline and accepts the uncertainty inherent in any development pipeline.
     
  8. Anonymous

    Anonymous Guest

    Ditto!
     
  9. Anonymous

    Anonymous Guest

    Go do some real stock research you Hedge-Funded, paid stock-basher. I know who you are.
     
  10. Anonymous

    Anonymous Guest

    From an outsiders point of view. Watching these arguments, no matter if an employee, past employee, etc. is always telling... You watch the price drop on the stock and an old employee tells you why. An employee says it is all garbage, yet, only has to say to EX employee "go away"...

    This is alway the employees oppurtunity to state... We are doing X,Y,and Z. Plus A, B, and D are right around the corner... vs telling either basher, or ex employee to "go away" THat is a huge "tell" in itself. Had the price been headed higher, then one could possibly construe the opposite. Yet, notta happening and so goes the once promising SGEN... Seem Baker loves to use this as a register to fund his life style.

    Feel sorry for those involved. Really, is there any other biotech in this country with higher expectation floundering so hard...

    Too bad... Good luck and hopefully they nail something else really soon...
     
  11. Anonymous

    Anonymous Guest

    You are way off base my friend. If you know anything about the business or the company you should know that the value of a company is not necessarily reflected in the stock price. Incredibly bright people work here. The company has a very bright future. Will there be a new product tomorrow. No, but there will be. Adcetris is moving towards a $1b product. Find another board to be a downer on.